R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Pharma 2025: AI, GLP-1 competition, and the future of clinic...

I’ve worked in clinical trials for twenty years. For most of that time, the core processes and challenges have been fairly consistent, with incremental improvements along the way.

R&D

Life Sciences Industry Report - Part 7 cover image

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.

R&D

JPM25 Steve Pakola interview with Jonah Comstock

JP Morgan Week 2025 – Steve Pakola

On the sidelines of JP Morgan in San Francisco, editor-in-chief Jonah Comstock caught up with Steven Pakola, REGENXBIO’s chief medical officer.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

R&D

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Life Sciences Industry Report - Rare Disease Space

There are some 7,000 known rare diseases in the world, yet, multiple challenges and unmet needs remain when it comes to therapies for these diseases.

R&D

Pharma holds it breath for ’25 as the sun shines on JP Morga...

The JP Morgan Healthcare Conference is seen as a barometer for the life sciences industry – and, going into this year’s event, the forecast for the year was particularly grim.